Drug duo may unlock kidney transplants for 'impossible' patients

NCT ID NCT05345717

Completed Disease control Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tested a combination of two drugs—belatacept and a proteasome inhibitor—to lower strong immune antibodies in 5 highly sensitized kidney transplant candidates. The goal was to increase their chances of finding a compatible donor. The study has completed, but results are not yet reported.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: belatacept and a proteasome inhibitor
What this could lead to: If successful, this could help more highly sensitized patients find a compatible kidney donor and receive a transplant.
What could go wrong: This is a very small pilot study with only 5 participants, so results may not apply to everyone. The drugs also carry risks like infection and allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END STAGE KIDNEY DISEASE (ESRD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

END STAGE KIDNEY DISEASE (ESRD) KIDNEY TRANSPLANTATION

Contacts and locations

Locations

University of Chicago

Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.